|
Antibody Response after ChAdOx1 nCoV-19 Vaccination in Patients with Type 2 Diabetes at Vajira Hospital |
|---|---|
| รหัสดีโอไอ | |
| Creator | 1. Orawan Jedsadatud 2. Swangjit Suraamornkul |
| Title | Antibody Response after ChAdOx1 nCoV-19 Vaccination in Patients with Type 2 Diabetes at Vajira Hospital |
| Publisher | Text and Journal Publication |
| Publication Year | 2566 |
| Journal Title | Vajira Medical Journal |
| Journal Vol. | 67 |
| Journal No. | 1 |
| Page no. | 463-470 |
| Keyword | antibodies, chAdOx1 nCoV-19, COVID-19, COVID-19 vaccine, diabetes mellitus type 2 |
| URL Website | https://tci-thaijo.org/index.php/VMED |
| Website title | Vajira Medical Journal (วชิรเวชสาร) |
| ISSN | 0125-1252 |
| Abstract | OBJECTIVE: A question exists as to whether people with diabetes can respond effectively to the COVID-19 vaccine. This study aimed to evaluate antibody response after COVID-19 vaccination in patients with type 2 diabetes. METHODS: This was a cross-sectional analytical study. Two hundred and twelve type 2 diabetes patients were enrolled after receiving a second dose of the ChAdOx1nCoV-19vaccine 3 months previously. Demographic data, medical history, and blood drawn were collected. Antibodies against receptor binding domain (anti-RBD) was investigated in the laboratory department. Other factors that could affect anti-RBD level, i.e. age, gender, BMI, glycemic control, duration of diabetes, and comorbidity, were collected and analyzed. RESULTS: Among 212 patients with type 2 diabetes 3 months after receiving a second dose of the ChAdOx1nCoV-19 vaccine, the anti-RBD level mean was 989.56 U/ml. Patients with type 2 diabetes, with or without cardiovascular disease as a comorbidity, had median anti-RBD levels equal to 258 U/ml and 442 U/ml, respectively. The median of anti-RBD levels between groups had statistically significant differences (p-value = 0.021). Age, gender, BMI, duration of diabetes, glycemic control, and other comorbidities showed no statistically significant differences in the median anti-RBD levels. CONCLUSION: Only patients with type 2 diabetes with cardiovascular disease as a comorbidity showed statistically significant differences in Anti-SARS-CoV-2 response 3 months after receiving a second dose of the ChAdOx1nCoV-19 vaccine. Therefore, patients with diabetes and cardiovascular disease require earlier revaccination to ensure protection against COVID-19 infection. |
